Jubilant Cadista Pharmaceuticals
Jubilant Cadista Pharmaceuticals (United States) has no DMF, CEP or site registration linked in our records. 48 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Jubilant Cadista Pharmaceuticals: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/jubilant-cadista-pharmaceuticals
Overview
Jubilant Cadista Pharmaceuticals is a pharmaceutical company headquartered in Salisbury, United States.
FDA compliance signals
48 FDA enforcement records linked to this company.
- 4832025-01-15
Rejected in-process materials not quarantined
- 4832025-01-15
Records not made readily available to FDA
- 4832025-01-15
Signature and checking of records -- 2 persons
- 4832025-01-15
Systems in place to comply with verification requirements
- 4832025-01-15
Identification of Persons Performing Significant Steps
- recall — Class III2023-01-11
Subpotent Drug: Out of specification for assay at the 18-month stability timepoint.
- recall — Class II2022-08-03
Failed dissolution specifications.
- recall — Class II2022-08-03
Failed Dissolution Specifications
- recall — Class III2022-04-13
Subpotent
- recall — Class I2022-04-06
Labeling: Label mix-up: Incorrect label placed on product. Shipper cases labeled Meclizine Hydrochloride Tablets contain bottles incorrectly labeled as PredniSONE Tablets. The tablets in the bottles are Meclizine Hydrochloride
- recall — Class III2021-09-08
Subpotent
- recall — Class II2021-04-21
Failed Dissolution Specifications
- recall — Class III2021-03-10
Labeling: Illegible label: Customer complaint received of mis-alignment print of the printed dosing instructions on the blister card.
- recall — Class II2020-12-02
Failed Tablet/Capsule Specification
- recall — Class III2020-11-11
Subpotent
- recall — Class III2020-06-03
Presence of Foreign Substance visually consistent with the silica granules present in the desiccant packs utilized during storage of the product.
- recall — Class II2020-03-25
CGMP Deviations: Presence of dark brown discoloration on edges of tablets
- 4832020-02-28
Procedures for non-sterile drug products
- 4832020-02-28
Procedures to be written and followed
- recall — Class II2019-12-18
Presence of Foreign Substance: Presence of a foreign object in a single tablet.
- recall — Class II2019-10-23
CGMP Deviation: Presence of dark brown discoloration on edges of tablets.
- recall — Class I2019-08-07
Failed dissolution specifications : failed results at the 3-month stability time point.
- recall — Class II2019-04-10
Discoloration: Expansion of an earlier recall due to the presence of dark brown discoloration on the edges of the tablets.
- recall — Class III2019-03-13
Failed Dissolution Specifications; 9-monthstability timepoint
- recall — Class II2018-10-17
Discoloration: Presence of dark discoloration or brown spots on the edges of the tablets.
- recall — Class III2018-09-26
Failed Stability Specifications: An out-of-specification result was obtained during 18-month stability testing for assay.
- recall — Class III2018-08-29
Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.
- recall — Class III2018-08-29
Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.
- recall — Class III2018-08-29
Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.
- recall — Class III2018-08-29
Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.
- recall — Class III2018-06-13
Incorrect/Undeclared excipient: Product batches were released into commercial distribution with a larger size grade of excipient (Crospovidone).
- recall — Class III2017-11-22
Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.
- recall — Class III2017-04-19
Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.
- recall — Class III2017-04-19
Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.
- recall — Class III2017-04-19
Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.
- recall — Class III2016-12-21
Labeling: Incorrect or Missing Lot and/or Exp Date: incorrect expiration date of 02/0218 is printed on the container label instead of the correct expiration date of 02/2018.
- 4832015-08-07
Complete test data included in records
- 4832015-08-07
Returned drug procedures in writing and followed
- 4832015-08-07
Scientifically sound laboratory controls
- 4832015-08-07
SOPs not followed / documented
- 4832015-08-07
Cleaning / Sanitizing / Maintenance
- 4832015-08-07
Training , Education , Experience overall
- 4832015-08-07
Rejected Material Area
- recall — Class II2014-08-06
Presence of Foreign Substance: Tablets may contain dark blemishes identified as stainless steel.
- recall — Class II2013-05-08
cGMP Deviations: Oral products were not manufactured in accordance with Good Manufacturing Practices.
- 4832011-03-23
Written program not followed
- 4832011-03-23
Investigations of discrepancies, failures
- 4832011-03-23
Failing drug products not rejected
Is this Jubilant Cadista Pharmaceuticals?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.